These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15848601)

  • 21. Effects of combination therapy with angiotensin II type I receptor blockers and calcium channel blockers on renal function in hypertensive patients/a retrospective, "real-world" comparative study.
    Yamada H; Suga N; Maeda K; Kimura Y; Miura N; Futenma A; Imai H
    Arzneimittelforschung; 2010; 60(2):64-70. PubMed ID: 20329653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease.
    Matsuda H; Hayashi K; Homma K; Yoshioka K; Kanda T; Takamatsu I; Tatematsu S; Wakino S; Saruta T
    Hypertens Res; 2003 Nov; 26(11):875-80. PubMed ID: 14714578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
    Cice G; Ferrara L; Tagliamonte E; Russo PE; Di Benedetto A; Iacono A
    Cardiologia; 1999 Dec; 44(12):1071-6. PubMed ID: 10687258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of combination of cyclosporine with losartan or enalapril on kidney function in uremic rats.
    Azzadin A; Małyszko J; Małyszko JS; Tankiewicz A; Myśliwiec M; Buczko W
    Pol J Pharmacol; 2002; 54(5):469-73. PubMed ID: 12593533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of low-dose cyclosporine therapy before transplantation in kidney allograft recipients.
    Khosroshahi HT; Badrogli N; Jahannavard N; Oskuii R; Bahluli A; Azar SA; Ardalan M
    Transplant Proc; 2009 Sep; 41(7):2757-60. PubMed ID: 19765427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients.
    Suwelack B; Kobelt V; Erfmann M; Hausberg M; Gerhardt U; Rahn KH; Hohage H
    Transpl Int; 2003 May; 16(5):313-20. PubMed ID: 12759722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal function in cardiac transplant recipients: retrospective analysis of 133 consecutive patients in a single center.
    Tinawi M; Miller L; Bastani B
    Clin Transplant; 1997 Feb; 11(1):1-8. PubMed ID: 9067686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nifedipine improves immediate, and 6- and 12-month graft function in cyclosporin A (CyA) treated renal allograft recipients.
    Harper SJ; Moorhouse J; Veitch PS; Horsburgh T; Walls J; Bell PR; Donnelly PK; Feehally J
    Transpl Int; 1992; 5 Suppl 1():S69-72. PubMed ID: 14621737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
    Suzuki H; Kanno Y; Sugahara S; Ikeda N; Shoda J; Takenaka T; Inoue T; Araki R
    Am J Kidney Dis; 2008 Sep; 52(3):501-6. PubMed ID: 18653268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal hemodynamics in hypertensive renal allograft recipients: effects of calcium antagonists and ACE inhibitors.
    Grekas D; Dioudis C; Kalevrosoglou I; Alivanis P; Derveniotis V; Tourkantonis A
    Kidney Int Suppl; 1996 Jun; 55():S97-100. PubMed ID: 8743523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
    Ogawa S; Takeuchi K; Mori T; Nako K; Tsubono Y; Ito S
    Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular and clinical response to angiotensin II receptor antagonist in kidney transplant patients with chronic allograft nephropathy.
    Mas VR; Alvarellos T; Maluf DG; Ferreira-Gonzalez A; Oliveros L; Maldonado RA; de Boccardo G
    Transpl Int; 2004 Oct; 17(9):540-4. PubMed ID: 15349718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors and prognosis for proteinuria in renal transplant recipients.
    Sancho A; Gavela E; Avila A; Morales A; Fernández-Nájera JE; Crespo JF; Pallardo LM
    Transplant Proc; 2007 Sep; 39(7):2145-7. PubMed ID: 17889119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients.
    Hamada T; Ichida K; Hosoyamada M; Mizuta E; Yanagihara K; Sonoyama K; Sugihara S; Igawa O; Hosoya T; Ohtahara A; Shigamasa C; Yamamoto Y; Ninomiya H; Hisatome I
    Am J Hypertens; 2008 Oct; 21(10):1157-62. PubMed ID: 18670416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy.
    Boman K; Boman JH; Andersson J; Olofsson M; Dahlöf B
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):146-52. PubMed ID: 19825910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of cyclosporine on regulators of fibrinolysis in plasma from renal allograft recipients.
    Elhasade AS; Perkowska A; Paczek L; Rowiński W; Soluch L; Szmidt J; Gałazka Z; Gaciong Z
    Ann Transplant; 1998; 3(1):13-8. PubMed ID: 9869892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
    Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
    Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K; Hayashi K; Kanda T; Yoshioka K; Takamatsu I; Tatematsu S; Kumagai H; Wakino S; Saruta T
    J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.